Mehdi Hamadani, MD
Medical College of Wisconsin
5
4
2
N/A
0
9
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+8 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Sameem Abedin, MD
Medical College of Wisconsin
Shared therapeutic areas:
Worked with same sponsors:
John Levine, MD
Icahn School of Medicine at Mount Sinai
Shared therapeutic areas:
Worked with same sponsors:
Michael Craig, MD
West Virginia University
Shared therapeutic areas:
Worked with same sponsors:
Gabrielle Meyers, MD
Oregon Health and Science University
Shared therapeutic areas:
Worked with same sponsors:
Jae Park, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Worked with same sponsors:
Helen Heslop, MD
Baylor College of Medicine
Shared therapeutic areas:
Worked with same sponsors:
Li Yu, Dr
Shenzhen University General Hospital
Shared therapeutic areas:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Partow Kebriaei, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)
MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation
Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation
CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation
All 5 trials loaded